A daily stock analysis based on stock market today
  • Daily Roll
  • YouTube
  • Podcast
  • Investor Hubs
    • Starter Investors Hub
    • Dividend Seekers Hub
    • The Risk Hub
    • COVID-19 Investing Hub
  • Sign Up
  • Boot Camp

2 ETFs for the Future of Gene-Editing: ARKG & GNOM

8/18/2021

 

KEY POINTS

  • The Federal Reserve is considering tapering back it’s economic support soon, and the market dropped in response.
  • Both Lowe’s (LOW) and Home Depot (HD) posted earnings this week, but share prices have gone opposite directions.
  • A new development in gene-editing technology gave investors the conviction to double down on gene-editing stocks.

OVERALL MARKET

The Federal Reserve is considering tapering back its economic support soon, and the market dropped in response.
Picture
The market indices ended the day in the red once again.

We discussed the remarks by some Fed officials about the tapering of some favorable monetary policies. We received more concrete evidence for it today. The market's slide today is mostly due to the Federal Reserve’s July meeting transcripts that were released today. It shows that some members of the Fed were looking to reduce its asset-buying practice sooner rather than later, possibly as soon as this year. These members used the price stability and employment numbers as examples for why the government could ease off on supporting the economy. In response, stocks took a noticeable dive today.

GET THE DAILY MARKET RECAP

Did you know you can get your Daily Market recap report on YouTube, listen to it on our Podcast, or get it in your inbox?

Watch it,  
Listen to it,  
Or, read it. 
 
Sign up for a free Stock Card account to get the report in your mailbox every day.
GIVE STOCK CARD A TRY!

WHAT'S UP?

Both Lowe’s (LOW) and Home Depot (HD) posted earnings this week, but share prices have gone opposite directions.
Today, I was browsing the list of winners on Stock Card and Lowe’s Companies (LOW) caught my eye. Lowe’s is the second-largest home improvement retailer in the world, so I wondered what could have moved the stock 10% in a session. Before today, the stock was at its lowest point in nine months. It seems that it was sliding quickly based on Home Depot’s (HD) subpar earnings report from two days ago. Investors looked at the HD's disappointing same-store sales growth and assumed Lowe’s would share the same picture.

Fortunately, Lowe’s had decent earnings and a good financial outlook today, which was enough to please the pessimistic investors. Home Depot’s CEO had blamed inflation such as lumber prices for its impacted sales, and while that certainly affected Lowe’s as well, its management is taking a more optimistic approach. Home Depot didn’t give a financial outlook due to rising COVID cases, yet Lowe’s raised its forecast for the rest of the year despite acknowledging that there was uncertainty.

Lowe’s Stock Card is a nice 3-greener. Home Depot has similar ratings, but its stock price is a little more expensive, and it has posted a worse return on investment over the past year, or three, compared to Lowe’s. If you are trying to pick between these two home improvement giants, Lowe’s is looking like your better bet. I don't own either of the two. 

ETF SPOTLIGHT

A new development in gene-editing technology gave investors the conviction to double down on gene-editing stocks.
As part of my market research today, I noticed the number of gene-editing stocks that ARK Invest picked up yesterday on its trades tracker on the ARK website. It got me curious as to why Cathie Wood and her team decided to scoop up so many genome shares this particular week. 

Some of you who follow my portfolios on Stock Card know that I’m a big fan of the future of gene editing. It’s a megatrend that will be shaping much of our future! A while back, I split $10,000 between 10 gene-editing stocks and I’m planning to hold them and go long.

Back to ARK, according to ARK Invest's latest newsletter, there’s been a great breakthrough from the researchers at Harvard and Howard Hughes. They call the new technology “prime editing,” and it’s going to help us treat a wider range of conditions, and do it more effectively. The main advantage to prime editing is how much neater the process is when editing a strand of DNA. Prime editing allows researchers to “copy” new information onto DNA without risking damage. This is another step towards gene-editing that can benefit our entire society. That perfectly explains why Cathie and her team got a stronger conviction about the future of gene editing stocks. 

While I picked 10 gene-editing stocks to ride the wave, it's also possible to buy gene-editing-focused ETFs and simplify your process. Here’s two I like:
  • First off, Cathy Woods has an ETF specifically for this reason. Type the ticker “ARKG” into the search bar on Stock Card, and get ARK Genomic Revolution ETF (ARKG). 
  • On the other hand, you can also check out the Global X Genomics & Biotechnology ETF (GNOM) as well by searching its ticker, “GNOM” on Stock Card. This is a similar fund that aims to benefit from advances in genome science and biotechnology. 

Let me know in the comments if you’re joining me as a shareholder of the megatrend that is gene-editing!

FEATURED PARTNER PORTFOLIO

Stock Card partner Brian Feroldi breaks down Shopify (SHOP) in his newest video.
Folks, you know that here at Stock Card, we like to partner with successful investors who can share their research, stock picks, and analysis with you. Brian Feroldi & Brian Stoffel run a YouTube channel where they break down and analyze stocks we all want to own.

Yesterday, they released a video where they dug into Shopify (SHOP) stock. I would highly recommend that you check out their video! 

Also, both Brians are intelligent investors who share their portfolios on Stock Card on the Stock Picks page. Brian Feroldi runs two: a Quality Checklist Portfolio and an interesting Anti-Portfolio, which consists of the stocks he reviews but doesn’t think quite stack up. Brian Stoffel also has two portfolios:  Fragile Portfolio and Anti-fragile Portfolio.

Make sure to follow them both on Stock Card to be notified when they add a stock to their portfolios.

WANT TO RECEIVE THIS DAILY STOCK MARKET REPORT IN YOUR MAILBOX?

Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
GIVE STOCK CARD A TRY!

    RSS Feed


    Archives

    December 2022
    September 2022
    July 2022
    February 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    February 2021
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    January 2020
    October 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017

    Categories

    All
    Battle
    Education
    ETF Investing
    How To Invest
    New Podcast Episode
    New Portfolio
    Portfolio Update
    Starter 2020
    Stock Card VIP Pick
    Stock Lists
    The Daily Hype
    Update
    Watchlist Worthy
    Winners And Losers

© 2023 StockCard.io. All Rights Reserved.
​​
Disclaimer: StockCard.io is not, neither operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on StockCard.io and Stock Card Weekly represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The Stock Card team may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall StockCard.io be liable to any subscriber, visitor, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on StockCard.io, or relating to the use of, or inability to use, StockCard.io or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
  • Daily Roll
  • YouTube
  • Podcast
  • Investor Hubs
    • Starter Investors Hub
    • Dividend Seekers Hub
    • The Risk Hub
    • COVID-19 Investing Hub
  • Sign Up
  • Boot Camp